Inhaled Technosphere Insulin

Small molecule

Inhaled Technosphere Insulin is one of 32 small molecule programs targeting Gestational Diabetes. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gestational DiabetesActive, not recruiting

Gestational DiabetesPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Gestational Diabetes

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

28 2

Diabeta

Pfizer

Approved

8 3

Byetta

AstraZeneca

Approved

2 4

Victoza

Novo Nordisk

Approved

1 5

Folvite

Eli Lilly

Approved

1 6

Calciferol

Alnylam Pharmaceuticals

Actigall

Insulin 320

4 9

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

1 10

NOVOLIN R

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gestational Diabetes1 trial

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Recruiting·JJaeb Center for Health Research·Phase 2/3·NCT06535789·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled Technosphere Insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled Technosphere Insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled Technosphere Insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jaeb Center for Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJaeb Center for Health Research

Inhaled Technosphere Insulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gestational Diabetes1 trial

References

Drug Info

Quick Facts

Related News